Shin Ahn1, Yoon-Seon Lee, Kyung Soo Lim, Jae-Lyun Lee. 1. Cancer Emergency Room, Department of Emergency Medicine, Asan Medical Center, University of Ulsan College of Medicine, 388-1, Pungnap-dong, Songpa-gu, Seoul, 138-736, South Korea. ans1023@gmail.com
Abstract
PURPOSE: Infectious complication could be life-threatening in patients with chemotherapy-induced febrile neutropenia (FN). The Multinational Association of Supportive Care in Cancer (MASCC) risk-index score is used to predict the complications of these patients, and it has been focused on identifying low-risk patients who may be candidates for outpatient management. In this study, we evaluated procalcitonin (PCT) and the MASCC score in predicting bacteremia and septic shock in patients with FN. METHODS: From November 2010 to October 2011, 355 patients with FN were prospectively enrolled. Clinical and laboratory findings, including procalcitonin, and the MASCC score were analyzed and correlated with the infectious complications of FN. RESULTS: Of the 355 patients, 35 (9.9 %) had bacteremia, and 25 (7.0 %) developed septic shock. PCT ≥ 0.5 ng/mL (OR 3.96, 95 % CI 1.51-10.40), platelet count <100 × 10(3)/mm(3) (OR 2.50, 95 % CI 1.10-5.66), and MASCC score <21 (OR 2.45, 95 % CI 1.03-5.85) were independently predictive of bacteremia, and PCT ≥ 1.5 ng/mL (OR 29.78, 95 % CI 9.10-97.39) and MASCC score <21 (OR 9.46, 95 % CI 3.23-27.72) were independent factors of septic shock. In 306 patients with low-risk FN classified by the MASCC score, 52 had PCT ≥ 0.5 ng/mL and 31 had PCT ≥ 1.5 ng/mL. Of the 52 patients with PCT ≥ 0.5 ng/mL, 12 (23.1 %) had bacteremia, and of the 31 patients with PCT ≥ 1.5 ng/mL, 7 (22.6 %) developed septic shock. CONCLUSION: Implicating PCT as a routine use in clinical practice along with the MASCC score could improve risk stratification of patients with FN.
PURPOSE: Infectious complication could be life-threatening in patients with chemotherapy-induced febrile neutropenia (FN). The Multinational Association of Supportive Care in Cancer (MASCC) risk-index score is used to predict the complications of these patients, and it has been focused on identifying low-risk patients who may be candidates for outpatient management. In this study, we evaluated procalcitonin (PCT) and the MASCC score in predicting bacteremia and septic shock in patients with FN. METHODS: From November 2010 to October 2011, 355 patients with FN were prospectively enrolled. Clinical and laboratory findings, including procalcitonin, and the MASCC score were analyzed and correlated with the infectious complications of FN. RESULTS: Of the 355 patients, 35 (9.9 %) had bacteremia, and 25 (7.0 %) developed septic shock. PCT ≥ 0.5 ng/mL (OR 3.96, 95 % CI 1.51-10.40), platelet count <100 × 10(3)/mm(3) (OR 2.50, 95 % CI 1.10-5.66), and MASCC score <21 (OR 2.45, 95 % CI 1.03-5.85) were independently predictive of bacteremia, and PCT ≥ 1.5 ng/mL (OR 29.78, 95 % CI 9.10-97.39) and MASCC score <21 (OR 9.46, 95 % CI 3.23-27.72) were independent factors of septic shock. In 306 patients with low-risk FN classified by the MASCC score, 52 had PCT ≥ 0.5 ng/mL and 31 had PCT ≥ 1.5 ng/mL. Of the 52 patients with PCT ≥ 0.5 ng/mL, 12 (23.1 %) had bacteremia, and of the 31 patients with PCT ≥ 1.5 ng/mL, 7 (22.6 %) developed septic shock. CONCLUSION: Implicating PCT as a routine use in clinical practice along with the MASCC score could improve risk stratification of patients with FN.
Authors: Walter T Hughes; Donald Armstrong; Gerald P Bodey; Eric J Bow; Arthur E Brown; Thierry Calandra; Ronald Feld; Philip A Pizzo; Kenneth V I Rolston; Jerry L Shenep; Lowell S Young Journal: Clin Infect Dis Date: 2002-02-13 Impact factor: 9.079
Authors: Marianne Paesmans; Jean Klastersky; Johan Maertens; Aspasia Georgala; Frédérique Muanza; Mickael Aoun; Augustin Ferrant; Bernardo Rapoport; Ken Rolston; Lieveke Ameye Journal: Support Care Cancer Date: 2010-07-02 Impact factor: 3.603
Authors: Lothar Hambach; Matthias Eder; Elke Dammann; Andreas Schrauder; Karl-Walter Sykora; Christian Dieterich; Philip Kirschner; Jürgen Novotny; Arnold Ganser; Bernd Hertenstein Journal: Haematologica Date: 2002-06 Impact factor: 9.941
Authors: J Klastersky; M Paesmans; E B Rubenstein; M Boyer; L Elting; R Feld; J Gallagher; J Herrstedt; B Rapoport; K Rolston; J Talcott Journal: J Clin Oncol Date: 2000-08 Impact factor: 44.544
Authors: J Klastersky; L Ameye; J Maertens; A Georgala; F Muanza; M Aoun; A Ferrant; B Rapoport; K Rolston; M Paesmans Journal: Int J Antimicrob Agents Date: 2007-08-08 Impact factor: 5.283
Authors: Byuk Sung Ko; Shin Ahn; Yoon-Seon Lee; Won Young Kim; Kyung Soo Lim; Jae-Lyun Lee Journal: Support Care Cancer Date: 2015-02-10 Impact factor: 3.603
Authors: Jeffrey M Caterino; David Adler; Danielle D Durham; Sai-Ching Jim Yeung; Matthew F Hudson; Aveh Bastani; Steven L Bernstein; Christopher W Baugh; Christopher J Coyne; Corita R Grudzen; Daniel J Henning; Adam Klotz; Troy E Madsen; Daniel J Pallin; Cielito C Reyes-Gibby; Juan Felipe Rico; Richard J Ryan; Nathan I Shapiro; Robert Swor; Arvind Venkat; Jason Wilson; Charles R Thomas; Jason J Bischof; Gary H Lyman Journal: JAMA Netw Open Date: 2019-03-01
Authors: Olaf Penack; Carolin Becker; Dieter Buchheidt; Maximilian Christopeit; Michael Kiehl; Marie von Lilienfeld-Toal; Marcus Hentrich; Marc Reinwald; Hans Salwender; Enrico Schalk; Martin Schmidt-Hieber; Thomas Weber; Helmut Ostermann Journal: Ann Hematol Date: 2014-04-29 Impact factor: 3.673
Authors: Luis García de Guadiana-Romualdo; Pablo Cerezuela-Fuentes; Ignacio Español-Morales; Patricia Esteban-Torrella; Enrique Jiménez-Santos; Ana Hernando-Holgado; María Dolores Albaladejo-Otón Journal: Biochem Med (Zagreb) Date: 2018-12-15 Impact factor: 2.313